Food Allergy

Pipeline Programs

Companies

Clinical Trials

3 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody

5100%

+ 10 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

SandozAustria - Kundl

2 programs

OmalizumabPhase 4Monoclonal Antibody1 trial

Ligelizumab 120 mgPhase 31 trial

Active Trials

NCT05678959Terminated163Est. Mar 2025

NCT04037176Completed20Est. Mar 2022

Allergy TherapeuticsUK - West Sussex

4 programs

Peanut ProteinPhase 21 trial

Natural History and Genetics of Food Allergy and Related ConditionsN/A1 trial

Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single SiteN/A1 trial

Registry of Food Allergy Oral Immunotherapy TreatmentN/A1 trial

Active Trials

NCT02504853Recruiting1,800Est. Jun 2026

NCT03539692Recruiting1,000Est. Dec 2028

NCT03059589Completed2,000Est. Dec 2020

+1 more trials

Angeles TherapeuticsCA - Los Angeles

2 programs

OmalizumabPhase 2Monoclonal Antibody1 trial

Active Trials

NCT03181009Completed60Est. Jan 2019

NCT02626611Completed70Est. Nov 2016

DBV TechnologiesFrance - Châtillon

1 program

Viaskin Milk 150 mcgPhase 1/21 trial

Active Trials

NCT02223182Completed198Est. Dec 2020

Thermo Fisher ScientificWALTHAM, MA

2 programs

walnut allergy provocationN/A1 trial

OmalizumabPHASE_4Monoclonal Antibody

Active Trials

NCT02295267Completed61Est. Mar 2017

AbbottABBOTT PARK, IL

1 program

Amino Acid-Based Experimental Study FormulaN/A1 trial

Active Trials

NCT04127656Terminated26Est. Dec 2021

Colorado TherapeuticsCO - Louisville

1 program

Evaluation of Potential Allergenicity of New Wheat VarietiesN/A1 trial

Active Trials

NCT02341040Terminated5Est. May 2018

RegeneronTARRYTOWN, NY

1 program

linvoseltamabPHASE_1Monoclonal Antibody1 trial

Active Trials

NCT06369467Recruiting6Est. Mar 2028

NovartisBASEL, Switzerland

1 program

Ligelizumab 120 mgPHASE_3

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

SandozOmalizumab

SandozLigelizumab 120 mg

Allergy TherapeuticsPeanut Protein

Angeles TherapeuticsOmalizumab

DBV TechnologiesViaskin Milk 150 mcg

Regeneronlinvoseltamab

AbbottAmino Acid-Based Experimental Study Formula

Allergy TherapeuticsPrescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site

Allergy TherapeuticsRegistry of Food Allergy Oral Immunotherapy Treatment

Allergy TherapeuticsNatural History and Genetics of Food Allergy and Related Conditions

Colorado TherapeuticsEvaluation of Potential Allergenicity of New Wheat Varieties

Thermo Fisher Scientificwalnut allergy provocation

Clinical Trials (13)

Total enrollment: 5,482 patients across 13 trials

NCT04037176 SandozOmalizumab

Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)

Start: Nov 2019Est. completion: Mar 202220 patients

Phase 4Completed

NCT05678959 SandozLigelizumab 120 mg

Long-term Extension Study of Ligelizumab in Food Allergy

Start: Apr 2023Est. completion: Mar 2025163 patients

Phase 3Terminated

NCT03907397 Allergy TherapeuticsPeanut Protein

Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy

Start: Aug 2019Est. completion: Nov 202373 patients

Phase 2Completed

NCT03181009 Angeles TherapeuticsOmalizumab

Multi OIT to Test Immune Markers After Minimum Maintenance Dose

Start: Jul 2017Est. completion: Jan 201960 patients

Phase 2Completed

NCT02626611 Angeles TherapeuticsOmalizumab

Multi Immunotherapy to Test Tolerance and Xolair

Start: Dec 2015Est. completion: Nov 201670 patients

Phase 2Completed

NCT02223182 DBV TechnologiesViaskin Milk 150 mcg

Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy

Start: Nov 2014Est. completion: Dec 2020198 patients

Phase 1/2Completed

NCT06369467 Regeneronlinvoseltamab

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Start: May 2024Est. completion: Mar 20286 patients

Phase 1Recruiting

NCT04127656 AbbottAmino Acid-Based Experimental Study Formula

Infants Fed an Amino Acid-based Formula

Start: Dec 2019Est. completion: Dec 202126 patients

N/ATerminated

NCT03539692 Allergy TherapeuticsPrescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site

Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site

Start: Jun 2018Est. completion: Dec 20281,000 patients

N/ARecruiting

NCT03059589 Allergy TherapeuticsRegistry of Food Allergy Oral Immunotherapy Treatment

Registry of Food Allergy Oral Immunotherapy Treatment

Start: Apr 2017Est. completion: Dec 20202,000 patients

N/ACompleted

NCT02504853 Allergy TherapeuticsNatural History and Genetics of Food Allergy and Related Conditions

Natural History and Genetics of Food Allergy and Related Conditions

Start: Jul 2015Est. completion: Jun 20261,800 patients

N/ARecruiting

NCT02341040 Colorado TherapeuticsEvaluation of Potential Allergenicity of New Wheat Varieties

Evaluation of Potential Allergenicity of New Wheat Varieties

Start: Nov 2014Est. completion: May 20185 patients

N/ATerminated

NCT02295267 Thermo Fisher Scientificwalnut allergy provocation

Molecular Analysis of IgE Antibodies in Walnut Allergic Patients

Start: Dec 2012Est. completion: Mar 201761 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals

3 actively recruiting trials targeting 5,482 patients

9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.